Meeting
2023 ASCO Annual Meeting
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
Authors
Andrew Peter Dean
St. John of God Hospital Subiaco, Subiaco, Australia
Andrew Peter Dean , Timothy Jay Price , Katrin Marie Sjoquist , Val Gebski , Jan Mumford , Fiona Day , Sonia Yip , Nathan Bradshaw , Christopher G. C. A. Jackson , Shamsudheen Padinharakam , Belinda Lee , Matthew E. Burge , Niall C. Tebbutt , Christopher B. Steer , Chris Lomma , Lyn Lam , Joanna Lee , Lorraine A. Chantrill , Marion Harris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05042128
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4197)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4197
Abstract #
TPS4197
Poster Bd #
505a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey